Literature DB >> 16261271

The Pediatric Heart Network: a primer for the conduct of multicenter studies in children with congenital and acquired heart disease.

L Mahony1, L A Sleeper, P A W Anderson, W M Gersony, B W McCrindle, L L Minich, J W Newburger, J P Saul, V L Vetter, G D Pearson.   

Abstract

Most contemporary diagnostic and treatment strategies for pediatric patients with cardiovascular disease are not supported by evidence from clinical trials but instead are based on expert opinion, single-institution observational studies, or extrapolated from adult cardiovascular medicine. In response to this concern, the National Heart, Lung, and Blood Institute established the Pediatric Heart Disease Clinical Research Network (PHN) in 2001. The purposes of this article are to describe the initiation, structure, and function of the PHN; to review the ongoing studies; and to address current and future challenges. To date, four randomized clinical trials and two observational studies have been launched. Design and conduct of complex, multicenter studies in children with congenital and acquired heart disease must address numerous challenges, including identification of an appropriate clinically relevant primary endpoint, lack of preliminary data on which to base sample size calculations, and recruitment of an adequate number of subjects. The infrastructure is now well developed and capable of implementing complex, multicenter protocols efficiently and recruiting subjects effectively. The PHN is uniquely positioned to contribute to providing evidence-based medicine for and improving the outcomes of pediatric patients with cardiovascular disease.

Entities:  

Mesh:

Year:  2006        PMID: 16261271     DOI: 10.1007/s00246-005-1151-9

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  13 in total

1.  Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group.

Authors:  H C Bucher; G H Guyatt; D J Cook; A Holbrook; F A McAlister
Journal:  JAMA       Date:  1999-08-25       Impact factor: 56.272

Review 2.  Do we measure the right end points? A systematic review of primary outcomes in recent neonatal randomized clinical trials.

Authors:  B Zhang; B Schmidt
Journal:  J Pediatr       Date:  2001-01       Impact factor: 4.406

Review 3.  End points for cardiovascular drug trials in pediatric patients.

Authors:  A R Sinaiko; R M Lauer; S P Sanders
Journal:  Am Heart J       Date:  2001-08       Impact factor: 4.749

4.  Report of the Task Force on Research in Pediatric Cardiovascular Disease.

Authors:  Claude Lenfant
Journal:  Circulation       Date:  2002-08-27       Impact factor: 29.690

5.  Development of cardiovascular drugs: the U.S. regulatory milieu from the perspective of a participating nonregulator.

Authors:  Jeffrey S Borer
Journal:  J Am Coll Cardiol       Date:  2004-12-21       Impact factor: 24.094

6.  Impact of the Hawthorne effect in a longitudinal clinical study: the case of anesthesia.

Authors:  D De Amici; C Klersy; F Ramajoli; L Brustia; P Politi
Journal:  Control Clin Trials       Date:  2000-04

Review 7.  NICHD neonatal research network: contributions and future challenges.

Authors:  Richard A Ehrenkranz; Linda L Wright
Journal:  Semin Perinatol       Date:  2003-08       Impact factor: 3.300

Review 8.  The multiple negative randomized controlled trials in perinatology--why?

Authors:  Marya Strand; Alan H Jobe
Journal:  Semin Perinatol       Date:  2003-08       Impact factor: 3.300

Review 9.  Clinical trials in children.

Authors:  Patrina H Y Caldwell; Sharon B Murphy; Phyllis N Butow; Jonathan C Craig
Journal:  Lancet       Date:  2004 Aug 28-Sep 3       Impact factor: 79.321

10.  Central challenges facing the national clinical research enterprise.

Authors:  Nancy S Sung; William F Crowley; Myron Genel; Patricia Salber; Lewis Sandy; Louis M Sherwood; Stephen B Johnson; Veronica Catanese; Hugh Tilson; Kenneth Getz; Elaine L Larson; David Scheinberg; E Albert Reece; Harold Slavkin; Adrian Dobs; Jack Grebb; Rick A Martinez; Allan Korn; David Rimoin
Journal:  JAMA       Date:  2003-03-12       Impact factor: 56.272

View more
  39 in total

1.  Rationale and methods for site selection for a trial using a novel intervention to treat stimulant abuse.

Authors:  Diane Warden; Madhukar H Trivedi; Tracy L Greer; Edward Nunes; Bruce D Grannemann; Viviana E Horigian; Eugene Somoza; Kolette Ring; Tiffany Kyle; José Szapocznik
Journal:  Contemp Clin Trials       Date:  2011-09-17       Impact factor: 2.226

2.  Comparison of shunt types in the Norwood procedure for single-ventricle lesions.

Authors:  Richard G Ohye; Lynn A Sleeper; Lynn Mahony; Jane W Newburger; Gail D Pearson; Minmin Lu; Caren S Goldberg; Sarah Tabbutt; Peter C Frommelt; Nancy S Ghanayem; Peter C Laussen; John F Rhodes; Alan B Lewis; Seema Mital; Chitra Ravishankar; Ismee A Williams; Carolyn Dunbar-Masterson; Andrew M Atz; Steven Colan; L LuAnn Minich; Christian Pizarro; Kirk R Kanter; James Jaggers; Jeffrey P Jacobs; Catherine Dent Krawczeski; Nancy Pike; Brian W McCrindle; Lisa Virzi; J William Gaynor
Journal:  N Engl J Med       Date:  2010-05-27       Impact factor: 91.245

Review 3.  Novel initiatives of the National Institutes of Health to support congenital heart disease research.

Authors:  Kristin M Burns; Gail D Pearson; Jonathan R Kaltman
Journal:  Curr Opin Pediatr       Date:  2013-10       Impact factor: 2.856

Review 4.  2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil.

Authors:  Craig A Sable; D Dunbar Ivy; Robert H Beekman; Helene D Clayton-Jeter; Kathy J Jenkins; William T Mahle; William R Morrow; Mary Dianne Murphy; Robert M Nelson; Geoffrey L Rosenthal; Norman Stockbridge; David L Wessel
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2017-07

5.  2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil.

Authors:  Craig A Sable; D Dunbar Ivy; Robert H Beekman; Helene D Clayton-Jeter; Kathy J Jenkins; William T Mahle; William R Morrow; Mary Dianne Murphy; Robert M Nelson; Geoffrey L Rosenthal; Norman Stockbridge; David L Wessel
Journal:  J Am Coll Cardiol       Date:  2017-06-29       Impact factor: 24.094

6.  Enalapril in infants with single ventricle: results of a multicenter randomized trial.

Authors:  Daphne T Hsu; Victor Zak; Lynn Mahony; Lynn A Sleeper; Andrew M Atz; Jami C Levine; Piers C Barker; Chitra Ravishankar; Brian W McCrindle; Richard V Williams; Karen Altmann; Nancy S Ghanayem; Renee Margossian; Wendy K Chung; William L Border; Gail D Pearson; Mario P Stylianou; Seema Mital
Journal:  Circulation       Date:  2010-07-12       Impact factor: 29.690

7.  Design and rationale of a randomized trial comparing the Blalock-Taussig and right ventricle-pulmonary artery shunts in the Norwood procedure.

Authors:  Richard G Ohye; J William Gaynor; Nancy S Ghanayem; Caren S Goldberg; Peter C Laussen; Peter C Frommelt; Jane W Newburger; Gail D Pearson; Sarah Tabbutt; Gil Wernovsky; Lisa M Wruck; Andrew M Atz; Steve D Colan; James Jaggers; Brian W McCrindle; Ashwin Prakash; Michael D Puchalski; Lynn A Sleeper; Mario P Stylianou; Lynn Mahony
Journal:  J Thorac Cardiovasc Surg       Date:  2008-05-19       Impact factor: 5.209

8.  A composite outcome for neonatal cardiac surgery research.

Authors:  Ryan J Butts; Mark A Scheurer; Sinai C Zyblewski; Amy E Wahlquist; Paul J Nietert; Scott M Bradley; Andrew M Atz; Eric M Graham
Journal:  J Thorac Cardiovasc Surg       Date:  2013-04-12       Impact factor: 5.209

9.  Opportunities and challenges in linking information across databases in pediatric cardiovascular medicine.

Authors:  Sara K Pasqual; Jennifer S Li; Marshall L Jacobs; Samir S Shah; Jeffrey P Jacobs
Journal:  Prog Pediatr Cardiol       Date:  2012-01

10.  Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome.

Authors:  Ronald V Lacro; Harry C Dietz; Lisa M Wruck; Timothy J Bradley; Steven D Colan; Richard B Devereux; Gloria L Klein; Jennifer S Li; L LuAnn Minich; Stephen M Paridon; Gail D Pearson; Beth F Printz; Reed E Pyeritz; Elizabeth Radojewski; Mary J Roman; J Philip Saul; Mario P Stylianou; Lynn Mahony
Journal:  Am Heart J       Date:  2007-10       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.